Enzo Biochem Inc
NYSE:ENZ
Intrinsic Value
Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable produ... [ Read More ]
The intrinsic value of one ENZ stock under the Base Case scenario is 1.48 USD. Compared to the current market price of 1.06 USD, Enzo Biochem Inc is Undervalued by 28%.
Valuation Backtest
Enzo Biochem Inc
Run backtest to discover the historical profit from buying and selling ENZ stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Enzo Biochem Inc
Current Assets | 80.9m |
Cash & Short-Term Investments | 60.2m |
Receivables | 5.1m |
Other Current Assets | 15.6m |
Non-Current Assets | 18.2m |
PP&E | 16m |
Other Non-Current Assets | 2.1m |
Current Liabilities | 25.3m |
Accounts Payable | 1.3m |
Accrued Liabilities | 8.4m |
Short-Term Debt | 3.2m |
Other Current Liabilities | 12.4m |
Non-Current Liabilities | 3m |
Long-Term Debt | 234k |
Other Non-Current Liabilities | 2.8m |
Earnings Waterfall
Enzo Biochem Inc
Revenue
|
63.5m
USD
|
Cost of Revenue
|
-42.6m
USD
|
Gross Profit
|
20.9m
USD
|
Operating Expenses
|
-57.6m
USD
|
Operating Income
|
-36.7m
USD
|
Other Expenses
|
32.1m
USD
|
Net Income
|
-4.6m
USD
|
Free Cash Flow Analysis
Enzo Biochem Inc
ENZ Profitability Score
Profitability Due Diligence
Enzo Biochem Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Enzo Biochem Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
ENZ Solvency Score
Solvency Due Diligence
Enzo Biochem Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Enzo Biochem Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ENZ Price Targets Summary
Enzo Biochem Inc
According to Wall Street analysts, the average 1-year price target for ENZ is 5.5 USD .
Ownership
ENZ Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ENZ Price
Enzo Biochem Inc
Average Annual Return | -15.75% |
Standard Deviation of Annual Returns | 31.12% |
Max Drawdown | -77% |
Market Capitalization | 53.5m USD |
Shares Outstanding | 51 230 000 |
Percentage of Shares Shorted | 1.86% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. The company is headquartered in Farmingdale, New York and currently employs 451 full-time employees. The firm develops, manufactures and sells technology solutions and platforms to clinical laboratories, specialty clinics, researchers and physicians globally. Enzo's segments include Enzo Clinical Lab, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Lab is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. Enzo Life Sciences manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. Enzo Therapeutics is a biopharmaceutical venture that developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one ENZ stock under the Base Case scenario is 1.48 USD.
Compared to the current market price of 1.06 USD, Enzo Biochem Inc is Undervalued by 28%.